fbpx
 

2020

CURE Epilepsy Research Continuity Fund

Modeling Drug-Refractory Epilepsy With the KaL Method

Braxton Norwood, PhD
Expesicor
 

Novel therapies are urgently needed that can bring seizure freedom to the one-third of epilepsy patients who, despite medication, suffer from intractable seizures. The development, validation, and implementation of new techniques that more accurately mimic human epilepsy are crucial first steps toward fulfilling this unmet need. To this end, former CURE Epilepsy grantee Dr. Norwood and his team at Expesicor are developing two novel laboratory models of drug-resistant human epilepsy, which will be used to discover and develop next-generation epilepsy therapies.

Dr. Norwood’s work is funded by the National Institutes of Health. The CURE Epilepsy Research Continuity Fund will help Dr. Norwood cover personnel time lost due to COVID shutdowns in April and May 2020 so that he and his team can finish developing their novel model of drug-resistant epilepsy.